GSK2838232

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

HIV InfectionsInfection, Human Immunodeficiency Virus

Phase 1

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

CompletedNCT01802918

GlaxoSmithKlineInfection, Human Immunodeficiency Virus

Start: 2013-02-18End: 2013-11-21Updated: 2017-05-09

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

TerminatedNCT02289495

GlaxoSmithKlineInfection, Human Immunodeficiency Virus

Start: 2014-11-18End: 2015-06-27Updated: 2017-05-09

Phase 2

Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults

CompletedNCT03045861

GlaxoSmithKlineHIV Infections, Infection, Human Immunodeficiency Virus

Start: 2017-03-17End: 2018-04-23Updated: 2020-03-11

Related Papers

A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection

Clinical Infectious Diseases2019-10-0327 citations